Carlsmed shares are down 6% since their July IPO, closing at $13.58 Friday, but Goldman Sachs started coverage with a Buy and a $19 target, implying 35% upside. Analysts cite salesforce growth, new cervical spine launch by 2026, and CMS reimbursement wins as key drivers. Retail traders stayed bearish despite the bullish Wall Street call.